Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.
Full description
Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation.
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased.
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant.
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.
Sex
Ages
Volunteers
Inclusion criteria
- Patients with amyloidosis
- NYHA class III or IV heart failure
- Patients undergoing heart transplant evaluation
- Patients less than 18 years of age
Exclusion criteria
- Patients who have unstable pulse and blood pressure
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal